Factor XIII Val34Leu polymorphism and ischaemic stroke in patients with patent foramen ovale

Thrombosis and Haemostasis

Volumn 102, Issue 6, 2009, Pages 1280-1282

  Wypasek, Ewa ^a,b   Stepien, Ewa ^a,b   Pieculewicz, Monika ^a   Podolec, Piotr ^a   Undas, Anetta ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 13; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUCINE; VALINE;

ADULT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; FEMALE; HOLTER MONITORING; HOMOZYGOSITY; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATENT FORAMEN OVALE; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; AMINO ACID SUBSTITUTION; CASE-CONTROL STUDIES; FACTOR V; FACTOR XIII; FEMALE; FIBRINOGEN; FORAMEN OVALE, PATENT; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTHROMBIN; STROKE;

EID: 72949117007     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-03-0144     Document Type: Letter

References (14)

1. Guercini F, Acciarresi M, Agnelli G, et al. Cryptogenic stroke: time to determine aetiology. J Thromb Haemost 2008; 6: 549-554.
2. Botto N, Spadoni I, Giusti S, et al. Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale. Stroke 2007; 38: 2070-2073.
3. Pezzini A, Del Zotto E, Magoni M, et al. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke 2003; 4: 28-33.
4. de la Red G, Tàssies D, Espinosa G, et al. Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels. Thromb Haemost 2009; 101: 312-316.
5. Rallidis LS, Politou M, Komporozos C, et al. Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb Haemost 2008; 99: 1085-1089.
6. Slowik A, Dziedzic T, Pera J, et al. Coagulation factor XIII VaI34Leu polymorphism in patients with small vessel disease or primary intracerebral hemorrhage. Cerebrovasc Dis 2005; 19: 165-170.
7. Hegele RA. SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol. 2002; 22: 1058-61.
8. Ariëns RA, Philippou H, Nagaswami C, et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-995.
9. Lim BC, Ariëns RA, Carter AM, et al. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-1431.
10. Austin H, Chimowitz MI, Hill HA, et al. Genetics and Stroke in the Young Study Group. Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women. Stroke 2002; 33: 2762-2768.
11. Pezzini A, Grassi M, Zotto ED, et al. Do common prothrombotic mutations influence the risk of cerebral ischaemia in patients with patent foramen ovale? Systematic review and meta-analysis. Thromb Haemost 2009; 101: 813-817.
12. Lalouschek W, Schillinger M, Hsieh K, et al. Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. Stroke 2005; 36: 1405-1409.
13. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706-708.
14. Jood K, Danielson J, Ladenvall C, et al. Fibrinogen gene variation and ischemic stroke. J Thromb Haemost 2008; 6: 897-904.